This federal Project Grant award, identified as K23HL168163, was made by the National Heart, Lung, and Blood Institute (NHLBI), which administers the Cardiovascular Diseases Research program (CFDA 93.837). The grant provides $195,480 in funding to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to investigate the effect of neprilysin inhibition on myocardial interstitial fibrosis, a key contributing factor to heart failure with preserved ejection fraction (HFPEF). The research aims to evaluate whether plasma levels of extracellular matrix regulatory proteins are associated with myocardial interstitial fibrosis, determine the impact of neprilysin inhibition on these proteins, and pilot a study assessing the effect of neprilysin inhibition on myocardial fibrosis. If successful, this work could help identify patients with myocardial fibrosis and evaluate potential anti-fibrotic therapies for HFPEF, which affects 2.5 million Americans. The award has an effective date of September 1, 2024 and is scheduled for completion on August 31, 2029.
Generated 3/25/25, 4:43 AM